

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.
Phone: 07405699869, email: info@vivanzabiosciences.com, website: www.vivanzabiosciences.com
CIN: L24110GJ1982PLC005057.

January 28, 2020

To,
The Department of Corporate Services
BSE Limited
25th Floor, P. J. Tower,
Dalal Street,
Fort, Mumbai - 400 001
BSE Script Code: 530057

Dear Sir/Madam,

Sub: Submission of standalone and consolidated unaudited financial results for the quarter and Nine Months ended 31st December, 2019.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we have pleasure in enclosing the standalone and consolidated unaudited financial results for the Quarter and Nine Months ended 31st December, 2019 together with the copies of the Limited Review Reports issued by the Statutory Auditors. These results were approved at the Board Meeting held today at the registered office of the Company.

The meeting of the Board of Directors of the Company commenced at 02.30 PM and concluded at 03.10 PM.

Please take the above on your records.

Thanking You.

Yours faithfully,
For Vivanza Biosciences Limited



Bhaskar Bhattacharya
Managing Director
DIN: 07487250



VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.

CIN : L24110GJ1982PLC005057

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2019.

(Rs. in Lacs except per share data)

Particulars	Quarter Ended			Nine Month Ended		Year Ended
	31/12/2019	30/09/2019	31/12/2018	31/12/2019	31/12/2018	31/03/2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income from Operations						
(a) Revenue from operations	312.33	0.00	0.00	363.55	102.64	222.19
(b) Other Income	4.23	0.00	0.00	4.23	0.00	0.00
Total Income	316.56	0.00	0.00	367.78	102.64	222.19
2 Expenses						
(a) Cost of Materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
(b) Purchase of stock-in-trade	302.72	0.00	0.00	180.00	41.64	161.19
(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	0.00	10.05	0.00	184.00	37.24	37.24
(d) Employee benefits expense	6.15	4.56	5.29	15.92	5.29	10.58
(e) Finance Cost	10.94	11.30	11.60	35.12	30.80	41.85
(f) Depreciation and amortisation expense	0.00	0.00	0.00	0.00	0.00	0.00
(g) Other expenses	11.28	3.30	1.96	17.97	9.77	16.23
Total Expenses	331.09	29.21	18.85	433.01	124.74	267.09
3 Profit/(loss) before exceptional items and tax (1-2)	-14.53	-29.21	-18.85	-65.23	-22.10	-44.90
4 Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
5 Profit/(Loss) before tax (3-4)	-14.53	-29.21	-18.85	-65.23	-22.10	-44.90
6 Tax Expense						
(a) Current tax	0.00	0.00	0.00	0.00	0.00	0.00
(b) Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
Total Tax Expenses	0.00	0.00	0.00	0.00	0.00	0.00
7 Profit / (Loss) for the period from continuing operations (5-6)	-14.53	-29.21	-18.85	-65.23	-22.10	-44.90
8 Profit (Loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
9 Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00	0.00
10 Profit (Loss) from discontinuing operations (after tax)	0.00	0.00	0.00	0.00	0.00	0.00
11 Other Comprehensive Income						
A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
Other Comprehensive Income for the period	0.00	0.00	0.00	0.00	0.00	0.00
12 Total Comprehensive Income for the period	-14.53	-29.21	-18.85	-65.23	-22.10	-44.90
Paid-up equity share capital (Face value of Rs. 10/- each)	400	400	400	400	400	400
13 Other Equity	-	-	-	-	-	-103.80
15 Earnings Per Share (before extraordinary items) (not annualised):						
(a) Basic	-0.36	-0.73	-0.47	-1.63	-0.55	-1.12
(b) Diluted	-0.36	-0.73	-0.47	-1.63	-0.55	-1.12
16 Earnings Per Share (after extraordinary items) (not annualised):						
(a) Basic	-0.36	-0.73	-0.47	-1.63	-0.55	-1.12
(b) Diluted	-0.36	-0.73	-0.47	-1.63	-0.55	-1.12

Notes:

1. The above standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on January 28, 2020. The Limited Review under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Limited Review Report does not contain any observation which could have an impact on the results for the quarter ended December 31, 2019.

2. The Company adopted the Indian Accounting Standards ('Ind AS') effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.

3. The Company operates only in single segment i.e. pharmaceuticals related activities

For, VIVANZA BIOSCIENCES LIMITED

Bhaskar
BHASKAR BHATTACHARYA
MANAGING DIRECTOR
DIN : 07487250

Date : 28/01/2020
Place : Ahmedabad

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.

CIN : L24110GJ1982PLC005057

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2019.

(Rs. in Lacs except per share data)

Particulars	Quarter Ended			Nine Month Ended		Year Ended	
	31/12/2019	30/09/2019	31/12/2018	31/12/2019	31/12/2018	31/03/2019	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1	Income from Operations						
	(a) Revenue from operations	312.33	0.94	6.58	365.10	132.08	265.94
	(b) Other Income	4.23	0.00	0.00	4.23	0.00	0.00
	Total Income	316.56	0.94	6.58	369.33	132.08	265.94
2	Expenses						
	(a) Cost of Materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Purchase of stock-in-trade	316.08	0.00	12.32	193.36	75.02	207.91
	(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	-13.40	10.99	0.00	171.70	33.48	27.87
	(d) Employee benefits expense	7.01	5.62	6.88	18.88	7.46	13.90
	(e) Finance Cost	10.94	11.30	11.60	35.12	30.80	41.85
	(f) Depreciation and amortisation expense	0.00	0.00	0.00	0.00	0.00	0.00
	(g) Other expenses	12.50	3.60	2.02	19.61	14.17	18.51
	Total Expenses	333.13	31.51	32.82	438.67	160.93	310.03
3	Profit/(loss) before exceptional items and tax (1-2)						
		-16.57	-30.57	-26.23	-69.34	-28.85	-44.09
4	Exceptional Items						
		0.00	0.00	0.00	0.00	0.00	0.00
5	Profit/(Loss) before tax (3-4)						
		-16.57	-30.57	-26.23	-69.34	-28.85	-44.09
6	Tax Expense						
	(a) Current tax	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
	Total Tax Expenses	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit / (Loss) for the period from continuing operations (5-6)						
		-16.57	-30.57	-26.23	-69.34	-28.85	-44.09
8	Profit (Loss) from discontinuing operations						
		0.00	0.00	0.00	0.00	0.00	0.00
9	Tax Expense of discontinuing operations						
		0.00	0.00	0.00	0.00	0.00	0.00
10	Profit (Loss) from discontinuing operations (after tax)(8-9)						
		0.00	0.00	0.00	0.00	0.00	0.00
11	Share of Profit / (Loss) of associates *						
		0.00	0.00	0.00	0.00	0.00	0.00
12	Minority Interest *						
		0.00	0.00	0.00	0.00	0.00	0.00
13	Other Comprehensive Income						
	A(i) Items that will not be reclassified to profit or loss						
		0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss						
		0.00	0.00	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss						
		0.00	0.00	0.00	0.00	0.00	0.00
	ii) Income tax relating to items that will be reclassified to profit or loss						
		0.00	0.00	0.00	0.00	0.00	0.00
	Other Comprehensive Income for the period						
		0.00	0.00	0.00	0.00	0.00	0.00
14	Total Comprehensive Income for the period						
		-16.57	-30.57	-26.23	-69.34	-28.85	-44.09
15	Total Comprehensive Income attributable to :						
	Share of Profit / (Loss) of associates *	0.00	0.00	0.00	0.00	0.00	0.00
	Minority Interest *	0.00	0.00	0.00	0.00	0.00	0.00
16	Paid-up equity share capital (Face value of Rs.10/- each)						
		400	400	400	400	400	400
17	Other Equity						
		-	-	-	-	-	(123.77)
18	Earnings Per Share (before extraordinary items) (not annualised):						
	(a) Basic	-0.41	-0.76	-0.66	-1.73	-0.07	-1.10
	(b) Diluted	-0.41	-0.76	-0.66	-1.73	-0.07	-1.10
19	Earnings Per Share (after extraordinary items) (not annualised):						
	(a) Basic	-0.41	-0.76	-0.66	-1.73	-0.07	-1.10
	(b) Diluted	-0.41	-0.76	-0.66	-1.73	-0.07	-1.10

Notes:

1. The above consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on January ,28,2020. The Limited Review under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Limited Review Report does not contain any observation which could have an impact on the results for the quarter ended December 31, 2019.

2. The Company adopted the Indian Accounting Standards ('Ind AS') effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.

3. The Company operates only in single segment i.e.pharmaceuticals related activities

For, VIVANZA BIOSCIENCES LIMITED

Bhaskar Bhattacharya
BHASKAR BHATTACHARYA
 MANAGING DIRECTOR
 DIN : 07487250



Date : 28/01/2020
 Place : Ahmedabad

**UDIN: 20163940AAAABL1642****Independent Auditor' s Review Report on Unaudited Standalone Quarterly and Nine Months Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To,
The Board of Directors,
Vivanza Biosciences Limited

We have reviewed the unaudited financial results of Vivanza Biosciences Limited (the "Company") for the Quarter and Nine Months ended 31st December, 2019 which are included in the accompanying Statement of Unaudited Financial Results for the Quarter and Nine Months ended 31st December 2019. The Statement has been prepared by the Company's management pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015") and SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5. 2016.

The Statement is the responsibility of the Company's management and has been approved by its board of directors. This Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("IND AS 34"), prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.


We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free from material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above , nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the (Listing Obligations and

Address : 101, Parishram, 5-B, Rashmi Society, Nr. LG Showroom, Mithakhali Six Roads, Navrangpura, Ahmedabad – 380009

☎ 079-40037372 ✉ gmca1973@gmail.com





GMCA & Co.

Chartered Accountants

Disclosure Requirements) Regulations, 2015 read with SEBI circular CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For, G M C A & CO.
Chartered Accountants
FRN: 109850W

M. S. Patel
CA. Mitt S. Patel
Partner

Membership No: 163940

Place: Ahmedabad

Date: 28th January, 2020

Address : 101, Parishram, 5-B, Rashmi Society, Nr. LG Showroom, Mithakhali Six Roads, Navrangpura, Ahmedabad – 380009

☎ 079-40037372 ✉ gmca1973@gmail.com



GMCA & Co.

Chartered Accountants

UDIN: 20163940AAAABM5916

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To,
The Board of Directors,
Vivanza Biosciences Limited

We have reviewed the accompanying statement of unaudited consolidated financial results of Vivanza Biosciences Limited ("the Holding Company"), and its subsidiaries, (collectively referred to as "the group") for the quarter and nine month ended December 31, 2019 ("the Statement") being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

This Statement, which is the responsibility of the Holding Company's Management and approved by the Board of Directors, has been compiled from the related interim financial statements, which has been prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), specified under Section 133 of the Companies Act, 2013 as applicable read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance about whether the financial statements are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)

Address : 101, Parishram, 5-B, Rashmi Society, Nr. LG Showroom, Mithakhali Six Roads, Navrangpura, Ahmedabad - 380009
☎ 079-40037372 ✉ gmca1973@gmail.com





GMCA & Co.

Chartered Accountants


Regulations, 2015 (as amended) and SEBI Circular dated 5th July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the Interim financial statements of Vivanza Lifesciences Pvt. Ltd. ("The Subsidiary") Pursuant to Ind AS 110, included in the statement. These interim financial results are reviewed by the Auditors of subsidiary company and have been furnished to us by the management of the group and our report on the consolidated financial results, in so far as it relates to the amounts included in respect of said subsidiary, is based solely on such reviewed & management certified interim financial results.



Place: Ahmedabad
Date: 28th January, 2020

For, G M C A & CO.
Chartered Accountants
FRN: 109850W


CA. Mitt S. Patel
Partner
Membership No: 163940

Address : 101, Parishram, 5-B, Rashmi Society, Nr. LG Showroom, Mithakhali Six Roads, Navrangpura, Ahmedabad – 380009
☎ 079-40037372 ✉ gmca1973@gmail.com